» Articles » PMID: 17684037

Lentiviral Vectors: Are They the Future of Animal Transgenesis?

Overview
Date 2007 Aug 9
PMID 17684037
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Lentiviral vectors have become a promising new tool for the establishment of transgenic animals and the manipulation of the mammalian genome. While conventional microinjection-based methods for transgenesis have been successful in generating small and large transgenic animals, their relatively low transgenic efficiency has opened the door for alternative approaches, including lentiviral vectors. Lentiviral vectors are an appealing tool for transgenesis in part because of their ability to incorporate into genomic DNA with high efficiency, especially in cells that are not actively dividing. Lentiviral vector-mediated transgene expression can also be maintained for long periods of time. Recent studies have documented high efficiencies for lentiviral transgenesis, even in animal species and strains, such as NOD/scid and C57Bl/6 mouse, that are very difficult to manipulate using the standard transgenic techniques. These advantages of the lentiviral vector system have broadened its use as a gene therapy vector to additional applications that include transgenesis and knockdown functional genetics. This review will address the components of the lentiviral vector system and recent successes in lentiviral transgenesis using both male- and female-derived pluripotent cells. The advantages and disadvantages of lentiviral transgenesis vs. other approaches to produce transgenic animals will be compared with regard to efficiency, the ability to promote persistent transgene expression, and the time necessary to generate a sufficient number of animals for phenotyping.

Citing Articles

Transgenesis and Genome Engineering: A Historical Review.

Montoliu L Methods Mol Biol. 2023; 2631:1-32.

PMID: 36995662 DOI: 10.1007/978-1-0716-2990-1_1.


Testis electroporation coupled with autophagy inhibitor to treat non-obstructive azoospermia.

Wang L, Liu C, Wei H, Ouyang Y, Dong M, Zhang R Mol Ther Nucleic Acids. 2022; 30:451-464.

PMID: 36420210 PMC: 9672891. DOI: 10.1016/j.omtn.2022.10.022.


Integrase deficient lentiviral vector: prospects for safe clinical applications.

Yew C, Gurumoorthy N, Nordin F, Tye G, Wan Kamarul Zaman W, Tan J PeerJ. 2022; 10:e13704.

PMID: 35979475 PMC: 9377332. DOI: 10.7717/peerj.13704.


Lentiviral interferon: A novel method for gene therapy in bladder cancer.

Mokkapati S, Narayan V, Manyam G, Lim A, Duplisea J, Kokorovic A Mol Ther Oncolytics. 2022; 26:141-157.

PMID: 35847448 PMC: 9251210. DOI: 10.1016/j.omto.2022.06.005.


Historical DNA Manipulation Overview.

Montoliu L Methods Mol Biol. 2022; 2495:3-28.

PMID: 35696025 DOI: 10.1007/978-1-0716-2301-5_1.